Mo­men­ta’s failed pan­cre­at­ic can­cer drug is giv­en a mid­night fu­ner­al

Pan­cre­at­ic can­cer has claimed an­oth­er biotech vic­tim. The tough on­col­o­gy tar­get proved re­sis­tant to Mo­men­ta Phar­ma­ceu­ti­cals’ necu­paranib at the halfway point in their Phase II study. And now the biotech $MN­TA has de­cid­ed to deep-six the drug and move on, ac­cord­ing to an SEC fil­ing.

Mo­men­ta’s 8-K, filed on Thurs­day, states:

Af­ter con­firm­ing the re­sults of the fu­til­i­ty analy­sis and re­view­ing the un­blind­ed safe­ty and ef­fi­ca­cy da­ta and the re­sults of var­i­ous sen­si­tiv­i­ty and sub­group analy­ses, the com­pa­ny de­cid­ed to dis­con­tin­ue the necu­paranib pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.